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Tubulointerstitial disease plays an important role in the
pathophysiology of diabetic kidney disease. To determine
whether biomarkers of tubular injury could predict renal
outcome and mortality in patients with type 2 diabetes, we
measured urinary levels of kidney injury molecule-1 (KIM-1)
and glycoprotein non-metastatic melanoma B (Gpnmb), both
normalized to the urinary creatinine, in 978 individuals from
the Edinburgh Type 2 Diabetes Study. At baseline, 238
patients had an estimated glomerular filtration rate (eGFR)
below 60ml/min/1.73m2 while 147 and 15 patients had
microalbuminuria or overt proteinuria, respectively. Both
the urine KIM-1 and Gpnmb to creatinine ratios correlated
with the urinary albumin to creatinine ratio, the duration
of diabetes, and the stringency of glycemic control but not
with blood pressure or baseline eGFR. Higher ratios of each
marker were associated with a faster decline in kidney
function during 4 years of follow-up; however, this was
not independent of the urinary albumin to creatinine ratio.
Higher KIM-1, but not Gpnmb ratios were associated with an
increased risk of mortality, but this association was no longer
significant after adjustment for other risk factors, in particular
albuminuria. Thus, tubular injury in persons with type 2
diabetes may contribute to the decline in kidney function;
however, measuring the urinary concentration of these two
tubular biomarkers does not confer additional prognostic
information beyond established risk factors.
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Diabetic kidney disease remains the single most common
cause of end-stage renal failure in the western world, acc-
ounting for almost half of incident cases in some countries.1
This is despite improvements in the management of patients
with diabetes, which have resulted in a reduction in the
prevalence of overt nephropathy after 30 years of type 1
diabetes to o15% in cohort studies,2 and to as little as 5%
in clinical trials.2,3 Given that only a small proportion of
diabetic patients develop overt nephropathy, development of
biomarkers that enable identification of those at greatest risk
would be useful in targeting therapeutic interventions.
Microalbuminuria indicates the presence of early glomer-
ular disease in patients with diabetes and remains the gold
standard for predicting progression to overt nephropathy
and end-stage renal failure.4 However, not all patients with
microalbuminuria will progress to nephropathy, and indeed
many will exhibit regression to normoalbuminuria.5 In type
1 diabetes, it has recently been established that markers of
tubular injury, such as urinary kidney injury molecule-1
(KIM-1), are elevated in patients with nephropathy6–9 and
that they may predict renal outcome. Urinary KIM-1 con-
centration correlates with the severity of proteinuria, falls in
response to renin–angiotensin system blockade, and predicts
decline in renal function, although not independently of pro-
teinuria.10 Furthermore, urinary KIM-1 concentration may
predict which patients will exhibit regression of microalbu-
minuria to normoalbuminuria.9
It has yet to be determined whether testing urinary KIM-1
concentration can also identify persons with type 2 diabetes,
who are at risk of progressive renal disease. In a small cohort
with type 2 diabetes, urinary KIM-1 concentration did not
correlate with established risk factors such as proteinuria.8
Furthermore, in comparison with type 1 diabetes, the pre-
valence of normoalbuminuric kidney disease is greater in
patients with type 2 diabetes, as other causes of nephropathy
such as renovascular disease, essential hypertension, and car-
diovascular disease are relatively more common.11 Whether
markers of tubular injury can predict prognosis in these
normoalbuminuric patients has yet to be investigated.
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Another potential tubular biomarker is glycoprotein non-
metastatic melanoma protein B (Gpnmb), a transmembrane
glycoprotein expressed on renal tubular cells and on cells
of the monocyte–macrophage lineage. We and others have
shown that it is elevated in rodent models of kidney disease
including diabetic nephropathy12,13 Interestingly, it is elevated
in mice in the reparative phase following renal ischemia–
reperfusion injury, and may promote renal repair, and hence
be a marker of tubular regeneration.14 The urinary excretion
of Gpnmb is elevated in patients with proteinuric renal
disease including diabetic nephropathy; however, the ability
of urinary Gpnmb concentration to predict renal outcomes
has not been assessed.13
The aims of the current study were to determine whether
urinary KIM-1 and Gpnmb concentrations were elevated in
patients with type 2 diabetes who had kidney disease, and
whether they could predict progression or regression of
microalbuminuria, the rate of decline in renal function,
and mortality in 978 patients from the Edinburgh Type 2
Diabetes Study (ET2DS), a large-scale (n¼ 1066), prospec-
tive, population-based cohort study of persons with type 2
diabetes aged 60–75 years from South-East Scotland.
RESULTS
Baseline characteristics
The baseline characteristics of the study population used in
the current analysis (978 participants from the ET2DS with
baseline urine available for biomarker measurement) are
shown in Table 1. In all, 69% of patients had blood pressures
of p140/80mmHg, whereas 44% and 83% had HbA1c
p7.0% andp8.0%, respectively. A total of 238 (24%) patients
had stage 3–5 chronic kidney disease (CKD), of whom the
majority (74%) were normoalbuminuric. Both the urinary
KIM-1 (uKIM-1)/Cr and urinary Gpnmb (uGpnmb)/Cr
ratios correlated with albumin/creatinine ratio (ACR), and
even more strongly with each other (Table 2). In addition,
both uKIM-1/Cr and uGpnmb/Cr ratios correlated with the
duration of diabetes and with the stringency of glycemic
control, but not with blood pressure or baseline estimated
glomerular filtration rate (eGFR).
Progression/regression of microalbuminuria
Follow-up ACR data were available for 945 subjects (97% of
the study population). During the course of the study, 103
(13%) persons who were normoalbuminuric at baseline
developed microalbuminuria or overt proteinuria. When
compared with persons with sustained normoalbuminuria,
those who subsequently developed microalbuminuria/pro-
teinuria had higher baseline ACR (1.4 vs. 0.99mg/mmol,
Po0.0001), but not significantly higher uKIM-1/Cr
(11.7 vs. 11.5 ng/mmol, P¼ 0.66) or uGpnmb/Cr (33.5 vs.
31.3 ng/mmol, P¼ 0.35) ratios. Conversely, 52 (35%) patients
who had microalbuminuria at baseline exhibited regression
to normoalbuminuria. The median baseline ACR was lower
in those who exhibited regression than in those with sustained
microalbuminuria (4.10 vs. 6.99mg/mmol, P¼ 0.0001),
whereas there were no differences in the median uKIM-1/Cr
(22.2 vs. 19.1 ng/mmol, P¼ 0.12) or uGpnmb/Cr ratios (43.9
vs. 41.4 ng/mmol, P¼ 0.99).
Factors predicting decline in renal function
Data on renal function during follow-up were available for
965 (99%) patients with a mean follow-up period of 3.6 years.
The mean (±s.e.m.) rate of decline in renal function during
follow-up was 0.35 (±3.87)ml/min per 1.73m2 per year.
Lower baseline HbA1c and systolic blood pressure were
independently associated with a slower rate of decline in
renal function (Table 3), whereas higher baseline ACR was
an independent risk factor for a more rapid deterioration in
renal function (Table 3, Figure 1). Higher uKIM-1/Cr and
uGpnmb/Cr ratios were associated with a faster decline in
renal function on univariate analysis (Table 3, Figure 1).
However, the association was no longer significant following
adjustment for known risk factors, such as baseline ACR,
HbA1c, systolic blood pressure, and eGFR (Table 3).
In patients with normoalbuminuria at baseline, a high
uKIM-1/Cr ratio, but not uGpnmb/Cr ratio, was associated
with a faster decline in renal function (b¼ 0.80, Po0.05), but
this was no longer significant following correction for established
risk factors such as HbA1c or systolic blood pressure (P40.05).
Risk of mortality
During the follow-up period, there were 75 deaths, compris-
ing 8% of the study population. Older patients and those
with lower baseline eGFR and higher baseline ACR were at
increased risk of mortality (Table 4). Although higher uKIM-
1/Cr ratios were associated with an increased risk of mortality
Table 1 | Baseline characteristics of the study population
Variable (n=978)
Sex (male) 515 (52.6%)
Age (years) 67.8 (±4.2)
Duration of diabetes (years) 8.1 (±6.5)
HbA1c (%) 7.4 (±1.1)
Systolic blood pressure (mmHg) 133 (±16.4)
Diastolic blood pressure (mmHg) 69 (±8.9)
eGFR (ml/min per 1.73m2) 71.9 (±17.8)
eGFR X60 740 (75.7%)
eGFR 30–59 218 (22.3%)
eGFR o30 20 (2.0%)
Albumin:creatinine ratio (mg/mmol) 1.17 (0.77–2.02)a
Normoalbuminuriab 816 (83.4%)
Microalbuminuriac 147 (15.0%)
Macroalbuminuriad 15 (1.5%)
Urinary KIM-1:creatinine (ng/mmol) 12.6 (7.6–22.8)a
Urinary Gpnmb:creatinine ratio (ng/mmol) 32.5 (21.3–50.7)a
Abbreviations: ACR, albumin:creatinine ratio; eGFR, estimated glomerular filtration
rate; Gpnmb, glycoprotein non-metastatic melanoma B; IQR, interquartile range;
KIM-1, kidney injury molecule-1.
Values are means (±s.e.m.).
aMedians (IQR) and n (%).
bNormoalbuminuria (ACRo2.5mg/mmol for males ando3.5mg/mmol for females).
cMicroalbuminuria (ACR 2.5–30 for males and 3.5–30 for females).
dMacroalbuminuria (ACR430mg/mmol).
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(Po0.05), the association did not remain statistically signif-
icant following adjustment for age, glycemic control, and
ACR (P40.05).
DISCUSSION
To our knowledge, this is the first study to examine the role
of tubular biomarkers in predicting decline of renal function
in patients with type 2 diabetes. The key findings are that
uKIM-1/Cr and uGpnmb/Cr ratios correlate with the severity
of proteinuria, and that higher uKIM-1/Cr and uGpnmb/Cr
ratios are associated with a faster decline in renal function.
However, neither uKIM-1/Cr nor Gpnmb/Cr ratios provided
additional prognostic information beyond measurement of
ACR alone. In addition, higher uKIM-1/Cr, but not Gpnmb/
Cr, ratios were associated with an increased risk of mortality,
although this association was no longer significant following
adjustment for established risk factors.
In contrast to a smaller study in persons with incipient
type 2 diabetic nephropathy,8 the uKIM-1/Cr ratio correlated
strongly with albuminuria, as did the uGpnmb/Cr ratio. This
is in keeping with studies in type 1 diabetes,6,9 and suggests
that there is a strong interrelationship between disease in the
glomerular and tubulointerstitial compartments of the
diabetic kidney, although the specific nature of this interac-
tion cannot be determined from observational studies alone.
It is possible that excess filtered albuminuria due to glome-
rular damage may cause tubular injury.15 Conversely, it has
been hypothesized that tubular dysfunction may be an
initiating factor in diabetic kidney disease, as in normoalbu-
minuric persons with type 1 diabetes, an elevated urinary
concentration of another tubular biomarker, liver-type fatty
acid–binding protein, precedes the onset of microalbumin-
uria.7 Although higher uKIM-1/Cr and Gpnmb/Cr ratios did
not predict subsequent microalbuminuria in the current
study, it may be that elevated tubular biomarkers in patients
with type 2 diabetes and normoalbuminuria represent tubular
injury secondary to diseases other than diabetic nephropathy,
such as renovascular disease, essential hypertension, or
other cardiovascular comorbidities, in which case they
would not be expected to precede microalbuminuria.
Indeed, although over 20% of the patients in the current
study had stage 3–5 CKD, approximately 75% of these
remained normoalbuminuric, a proportion similar to that
observed previously,16 suggesting that classical proteinuric
diabetic nephropathy was not responsible for the majority
of cases of CKD.
We had hypothesized that markers of tubular dysfunction
may confer additional diagnostic and prognostic information
to ACR for two reasons. First, they reflect damage in the
tubulointerstitial rather than the glomerular compartment,
and second, they may indicate the presence of active injury
rather than structural alterations due to previous insults.17
The elevated uKIM-1/Cr and Gpnmb/Cr ratios in patients
with incipient and overt nephropathy suggest that there is
ongoing tubular injury. Whether this has a major pathophy-
siological role in the deterioration of renal function cannot be
determined from the current study; however, the fact that
higher uKIM-1/Cr and Gpnmb/Cr ratios are associated with
a more rapid deterioration in renal function would support
this possibility. In addition, it would be consistent with renal
biopsy studies in which the degree of tubulointerstitial
damage predicted renal outcome.18
Table 2 | Correlation of urinary KIM/creatinine, Gpnmb/creatinine, and albumin/creatinine ratios with each other, and with
other baseline clinical variables
Log KIM-1/Cr
ratio
Log Gpnmb/
Cr ratio Log ACR Age
Duration of
diabetes HbA1c Systolic BP Diastolic BP Baseline eGFR
Log uKIM-1/
Cr ratio
— 0.62
(0.59, 0.66)
Po0.0001
0.31
(0.25, 0.36)
Po0.0001
0.10
(0.04, 0.16)
P=0.002
0.09
(0.03, 0.15)
P=0.004
0.09
(0.02, 0.15)
P=0.007
n.s. n.s. n.s.
Log
uGpnmb/Cr
ratio
0.62
(0.59–0.66)
Po0.0001
— 0.40
(0.35, 0.46)
Po0.0001
0.15
(0.09, 0.22)
Po0.0001
0.12
(0.05, 0.18)
P=0.0003
0.11
(0.04, 0.17)
P=0.001
0.073
(0.00, 0.13)
P=0.04
n.s. n.s.
Log ACR 0.31
(0.25, 0.36)
Po0.0001
0.40
(0.35, 0.46)
Po0.0001
— 0.08
(0.02, 0.14)
P=0.01
0.15
(0.09, 0.20)
Po0.0001
0.17
(0.10, 0.22)
Po0.0001
0.134
(0.1, 0.22)
Po0.0001
0.05
(0.11,0.01)
P=0.002
0.20
(0.26,0.14)
Po0.0001
Abbreviations: ACR, urinary albumin:creatinine ratio; BP, blood pressure; eGFR, estimated glomerular filtration rate; n.s., not significant; uGpnmb/Cr, urinary glycoprotein non-
metastatic melanoma B:creatinine ratio; uKIM-1/Cr, urinary kidney injury molecule-1:creatinine ratio.
Values are Pearson’s correlation coefficients (95% CI) and corresponding P-values.
Table 3 | Baseline variables associating with rate of change in
renal function by univariate and multivariate analysis
Univariate Multivariate
Variable b (s.e.) P-value b (s.e.) P-value
Duration of diabetes 0.06 (0.02) 0.001 n.s.
HbA1c 0.49 (0.11) o0.0001 0.57 (0.14) o0.0001
Systolic BP 0.03 (0.01) o0.0001 0.03 (0.01) 0.004
Baseline eGFR 0.03 (0.01) o0.0001 0.02 (0.07) 0.03
Log ACR 1.43 (0.30) o0.0001 1.60 (0.40) o0.0001
Log uKIM-1/Cr ratio 1.08 (0.31) o0.001 n.s.
Log uGpnmb/Cr ratio 0.96 (0.45) 0.03 n.s.
Abbreviations: ACR, urinary albumin:creatinine ratio; eGFR, estimated glomerular
filtration rate; n.s., not significant; uGpnmb/Cr, urinary glycoprotein non-metastatic
melanoma B:creatinine ratio; uKIM-1/Cr, urinary kidney injury molecule-1:creatinine ratio.
Values given are regression coefficients (s.e.).
Gender, age, duration of diabetes, and baseline HbA1c, systolic and diastolic blood
pressure, eGFR, log ACR, log uKIM-1/Cr, log uGpnmb/Cr were entered into the
multivariate analysis and serially removed until only those that remained independent
risk factors were included in the final analysis.
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The association between higher uKIM-1/Cr or uGpnmb/
Cr ratios and a greater rate of decline in renal function did
not remain significant following adjustment for standard
prognostic markers, in particular albuminuria, as has been
observed in type 1 diabetes.6 Similarly, the association
between higher uKIM-1/Cr ratios and mortality was not
independent of clinical parameters such as glycemic control
and ACR. This suggests that tubular biomarkers may not
confer any additional prognostic benefit beyond established
risk markers, and therefore, screening for tubular biomarkers
in persons with type 2 diabetes cannot be recommended for
prognostic use in routine clinical practice.
Although our results suggest that albuminuria remains the
gold standard as a prognostic marker in type 2 diabetes, the
majority of patients with declining renal function remained
normoalbuminuric. We had hypothesized that these patients
may have had predominantly tubulointerstitial disease and
that tubular biomarkers could therefore be of prognostic
benefit in normoalbuminuric patients. Higher urinary
KIM-1/creatinine ratios did indeed predict a faster decline
in renal function in this subset of patients; however, the
association was weak and was not independent of routine
clinical parameters such as systolic blood pressure or
HbA1c. Therefore, quantifying uKIM-1 concentration is an
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Figure 1 |Correlation between urinary biomarkers and rate of change in renal function. Scatter plots for (a) albumin:creatinine ratio;
(b) kidney molecule-1:creatinine ratio; and (c) glycoprotein non-metastatic melanoma B:creatinine ratio against rate of change in renal
function.
Table 4 | Cox proportional hazards for time to death according to baseline variables
Univariate Multivariate
Variable Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value
Age (years) 1.11 (1.05–1.17) o0.001 1.07 (1.01–1.14) 0.01
Diastolic BP (mmHg) 0.97 (0.95–1.00) o0.05 n.s.
eGFR (ml/min per 1.73m2) 0.97 (0.96–0.98) o0.0001 0.98 (0.97–0.99) o0.01
Log ACR 2.58 (1.75–3.8) o0.0001 2.00 (1.33–3.02) o0.001
Log uKIM-1/Cr 1.68 (1.00–2.83) o0.05 n.s.
Abbreviations: ACR, urinary albumin:creatinine ratio; CI, confidence intervals; eGFR, estimated glomerular filtration rate; n.s., not significant; uKIM-1/Cr, urinary kidney injury
molecule-1:creatinine ratio.
Hazard ratios given are for every 1 yr increase in age, 1mmHg increase in blood pressure, 1ml/min per 1.73m2 increase in eGFR, unit log increase in ACR or uKIM-1/Cr ratio.
Gender, age, duration of diabetes, baseline HbA1c, systolic and diastolic blood pressure, eGFR, log ACR, log uKIM-1/Cr, log uGpnmb/Cr were entered into the multivariate
analysis and serially removed until only those that remained independent risk factors for death were included in the final analysis.
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unlikely aid in risk stratification in normoalbuminuric
patients.
Although it has previously been reported that the
expression of Gpnmb is increased in rodents and patients
with diabetic nephropathy,12,13 this is the first assessment of
its utility as a prognostic biomarker. The uGpnmb/Cr ratio
did not predict mortality, and the association between the
uGpnmb/Cr ratio and the rate of change in renal function
was less strong than for either the uKIM-1/Cr ratio or ACR;
therefore, it cannot be recommended as a prognostic marker
in type 2 diabetes. It has been suggested that Gpnmb has an
important role in tubular regeneration following injury, as
tubular Gpnmb expression is not increased immediately
following ischemia–reperfusion injury but later during the
resolution phase.14 Therefore, in the setting of a chronic disease,
such as diabetic kidney disease, the elevated uGpnmb:Cr ratio
may reflect an attempt at renal repair amidst ongoing injury.
Indeed, a reduced Gpnmb/KIM-1 ratio was associated with a
greater rate of decline in renal function (Po0.05, data not
shown), suggesting that a failure to mount a regenerative
response may confer an increased risk of nephropathy.
To our knowledge, this is the largest study of the use
of tubular biomarkers in diabetic kidney disease. A major
strength of the study is that it is representative of the general
population of persons with type 2 diabetes, and therefore, it
is applicable to general practice and not subject to referral
bias. Conversely, it was not enriched for patients with pre-
existing diabetic nephropathy, and it is possible that tubular
biomarkers may have greater prognostic utility in this subset
of patients, although this was not observed in type 1
diabetes.6 Furthermore, although the follow-up is longer than
in previous studies,6,9 in the DCCT trial, it took almost a
decade for the effect of intensive glycemic control in
preventing a decline in renal function to become apparent;3
therefore, it may take many years before low-grade tubular
injury translates into a decline in eGFR. A further limitation
of the current study is that the decline in renal function was
calculated from just two estimates of GFR concentration
at baseline and after 4 years of follow-up. Some of the
fluctuations in eGFR may reflect acute kidney injury at the
time of blood sampling or changes in medications between
visits. We used the Chronic Kidney Disease Epidemiology
Collaboration (CKD-EPI) equation rather than Modification
of Diet in Renal Disease equation to estimate GFR, as it is
more accurate at the higher levels of renal function observed
in the majority of patients in the current study.19 However,
both equations are based on serum creatinine measurements,
and therefore, fluctuations in CKD-EPI eGFR may be influenced
by changes in muscle mass. Inaccuracies in determining the
true rate of decline in renal function may underestimate the
prognostic performance of a biomarker, as has been observed
when using serum creatinine to diagnose acute kidney
injury.20 However, our results are in keeping with those
obtained in type 1 diabetes using serial measurements of
‘true’ GFR as determined by isotope clearance.6 In addition,
little is known about the intra-day or day-to-day variability of
urinary tubular markers. Although we determined the
concentration of tubular markers in a single early morning
urine sample, it may be that a 24-h urine collection may
provide a more accurate assessment of KIM-1 excretion,
although this approach is unlikely to be practical for screening
purposes in the context of diabetic clinics. Alternatively, serial
spot measurements may overcome problems with variability
in a manner similar to microalbuminuria being defined from
the results of two out of three successive readings. It is
possible that concurrent hypertensive therapy may influence
the urinary concentration of tubular biomarkers and hence
their prognostic utility; however, including the presence/absence
of antihypertensive therapy at baseline as a categorical value
into the multivariable analysis had no significant impact on
the ability of tubular markers to predict either rate of decline
in renal function or mortality (date not shown).
In conclusion, in a large, prospective, population-based
study, higher uKIM-1/Cr and uGpnmb/Cr ratios were
associated with an increased rate of decline in renal function
over 4 years of follow-up, suggesting that tubular damage
makes an important contribution to kidney dysfunction
in patients with type 2 diabetes. In addition, higher uKIM-
1/Cr, but not uGpnmb/Cr ratios, conferred a higher risk
of mortality. However, neither the uKIM-1/Cr nor the
uGpnmb/Cr ratios independently predicted the rate of
decline in renal function or mortality after adjusting for
classical risk factors, in particular albuminuria, and there-
fore, routine testing of uKIM-1/Cr or uGpnmb/Cr ratios is
unlikely to confer additional prognostic information in
patients with type 2 diabetes.
MATERIALS AND METHODS
Patient recruitment
The ET2DS is a prospective cohort study of 1066 men and women
aged 60–75 years with established type 2 diabetes, living in the
Lothian region of Central Scotland, and recruited in 2006–2007. The
recruitment and baseline examination protocol have been described
in detail previously.21 Briefly, to establish a representative sample of
all persons with type 2 diabetes in the region, patients from the
Lothian Diabetes Register recorded as having type 2 diabetes were
randomly selected by sex and 5-year age bands to participate in the
study. Of the 5454 patients who were invited to participate, 1066
persons were recruited to the study, and these have been previously
demonstrated to be representative of all those who were invited to
participate and therefore of the target population of older men and
women with type 2 diabetes living in the Lothian region.22 A total of
978 (92%) subjects had a baseline urine sample available for testing
urinary biomarkers (the remaining samples were not stored
following urinary measurements in the baseline clinics), and these
subjects formed the study population for the current analysis. The
ET2DS was approved by the Lothian Medical Research Ethics
Committee. All subjects gave written informed consent, including
for follow-up and review of medical records.
Baseline data collection
At the baseline clinic visit, after an overnight fast, all participants
underwent venepuncture and provided an early morning urine
sample. The physical examination was completed by one of six trained
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nurses using standardized operating procedures, and included blood
pressure measurement using a sphygnomanometer. From the venous
blood sample, HbA1c and isotope dilution mass spectrometry–trace-
able serum creatinine levels were measured according to standard
protocols in the Department of Biochemistry, Western General
Hospital, Edinburgh, UK. The CKD-EPI equation was used to esti-
mate the GFR, as this has been shown to provide a more accurate
estimate than the four-variable Modification of Diet in Renal
Disease equation in patients with normal levels of renal function.19
Albumin and creatinine concentrations were determined using fresh
urine samples according to standard protocols in the Department of
Biochemistry, Western General Hospital, Edinburgh, UK. Urine was
then frozen at 201C until subsequent measurement of uKIM-1 and
uGpnmb concentrations was recorded using the enzyme-linked
immunosorbent assay kits (R&D systems, Minneapolis, MN)
according to the manufacturer’s instructions. The urinary KIM-1
and Gpnmb concentrations were then adjusted for urinary concen-
tration by expressing them relative to the urinary creatinine con-
centration.
Follow-up
Mortality during follow-up was assessed using a combination of
relative/family doctor notification and linkage to death records.
Subjects who were still alive were invited to re-attend the research
clinic 4 years after their initial visit. GFR was again estimated from
serum isotope dilution mass spectrometry–traceable creatinine
results using the CKD-EPI equation. Of the 978 persons from the
ET2DS study population, who had baseline urine samples available
for testing urinary biomarkers, 75 (8%) had died within 4 years and
137 (14%) were alive, but did not report for their 4-year follow-up
visit. For these 212 (21.7%) persons, the Lothian laboratory
database was interrogated to estimate GFR by the CKD-EPI
equation, based on the isotope dilution mass spectrometry–traceable
serum creatinine concentration at their last outpatient clinic visit.
In this way, we excluded rises in creatinine occurring as a result of
an acute illness. The rate of change in renal function was determined
by subtracting the Year 4 eGFR (or last outpatient eGFR for those
not attending the Year 4 visit) from the baseline eGFR, and dividing
by the time between measurements. For the entire study population
of 978 subjects, the Lothian laboratory database was also used to
determine the ACR at each clinic visit during follow-up. New-onset
microalbuminuria was defined as occurring in patients who were
normoalbuminuric at baseline, but who subsequently had an
ACR42.5 for men or43.5 for women in at least two of three con-
secutive readings at any point during the follow-up period. Conversely,
regression of microalbuminuria was defined as the presence of
microalbuminuria at the baseline research clinic measurement, with
a subsequent reversion to normoalbuminuria (ACRp2.5 for men
and p3.5 for women on at least two of three consecutive readings)
at any time during the follow-up period.
Statistical analysis
Data are expressed as means (±s.d.) and medians (interquartile
range), where the data are parametric (age, duration of diabetes,
HbA1c, systolic and diastolic blood pressure, baseline, and change in
eGFR), and nonparametric (ACR, uKIM-1/Cr, uGpnmb/Cr), respec-
tively. Nonparametric variables were log-transformed before further
analyses. Comparison of variables between groups was performed
using Student’s t-test. The extent of correlation between baseline
variables was assessed by Pearson’s correlation coefficient. Associa-
tion between baseline variables and rate of change in renal function
was assessed by univariate and multivariate linear regression analysis.
The risk of death conferred by baseline variables was determined by
Cox proportional hazards. Variables entered into the linear regres-
sion and Cox proportional hazards models included sex, age, duration
of diabetes, HbA1c, systolic and diastolic blood pressure, baseline
eGFR, whether patients were prescribed antihypertensive medica-
tions at the time of the baseline measurements, ACR, uKIM-1/Cr,
and uGpnmb/Cr, with only the variables that remained indepen-
dently significant being included in the final multivariate analyses.
A P-value of o0.05 was considered significant, and analyses were
performed using the GraphPad PRISM (version 4.00 for Windows,
GraphPad Software, San Diego, CA) or the Statview (version
5.0 for Windows, SAS Institute, San Francisco, CA) statistical
programs.
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